Replies to post #135084 on Biotech Values

[oc631]

Maybe even a private company like Alios will blindside IDIX speculators and deflate the balloon.

RFS Pharma is a fine example of a private company specializing in nucleoside chemistry which could potentially sell or license out a development stage asset (this article is over a year old).



http://www.drugs.com/clinical_trials/rfs-pharma-s-new-dioxolane-nucleoside-prodrugs-have-potent-selective-anti-hiv-activity-10904.html



"In addition, the company has identified very promising, early stage compounds for hepatitis C (some with picomolar activity in vitro), and also discovered a novel nucleoside technology along with analogs that are effective against noroviruses"


Now would be the opportune time for RFS to step up and do a deal.